Articles tagged with Blood Cancer
A phase 1 trial of ipilimumab, an immune checkpoint blocker, found clinical benefit in 45.4% of relapsed transplant patients, with notable responses in Hodgkin lymphoma and myelodysplastic syndrome. The six-month survival rate was 65%, with four patients remaining on treatment.
Researchers discovered that tamoxifen, a breast cancer drug, can target and control the survival and proliferation of stem cells responsible for blood cancers. The study found that activation of estrogen receptors with tamoxifen could block the excessive production of abnormal white blood cells in mice with blood neoplasms.
Two studies found a subset of somatic mutations in DNA samples from healthy individuals that significantly increase the risk of developing blood cancers. The 'pre-malignant' state becomes more common with age and can be detected by sequencing DNA from blood.
Scientists have identified a new therapeutic target, Mpl, which could lead to the development of novel treatments for myeloproliferative neoplasms (MPNs). The study found that reducing the expression of Mpl in laboratory models can prevent the development of mutant JAK2 disease.
Researchers have identified unique molecular fingerprints for 11 types of children's tumours, which could be used to develop blood tests to diagnose these cancers. This may eventually lead to a quicker and more accurate way to diagnose tumours.
A multi-center trial found similar survival rates in children with acute myeloid leukemia (AML) who received one or two units of partially matched cord blood. The study revealed improved recovery rates and lower risks of complications when using a double cord blood approach.
Researchers have linked age-related loss of the Y chromosome (LOY) to higher mortality and cancer rates in men. LOY was found to decrease men's lifespan by an average of 5.5 years, and increase their risk of dying from cancer.
Research at Washington University School of Medicine found that 2-5% of people over 40 and 70 have genetic mutations linked to leukemia and lymphoma. These mutations may be a precursor to blood cancers but do not guarantee development of the diseases.
Researchers successfully induced a rare type of blood cancer in mice using a single stem cell with the mutated JAK2 protein. The resulting cancer cells also retained the JAK2 mutation, offering new insights into the disease's progression.
Researchers developed a new blood test called the lymphocyte genome sensitivity (LGS) test, which can detect some cancers earlier than ever before. The test analyzes white blood cells exposed to UVA light and measures their DNA damage, allowing for early cancer detection and identifying those at risk of developing cancer.
A simple blood test could be used to identify patients at risk of cancer due to high levels of calcium in the blood. Researchers found that in men, even mild hypercalcaemia conferred a risk of cancer in one year of 11.5%, while in women, the corresponding figure was 4.1%. The study suggests that hyperparathyroidism may be responsible f...
Researchers have identified a gene network that fuels aggressive Acute Myeloid Leukemia and its precursor disease Myelodysplastic Syndrome. Inhibiting a key protein in this network may prevent leukemia cell growth and expansion.
Researchers at the University of Exeter Medical School have found that invisible blood in urine may be an early warning sign of bladder cancer. The risk of bladder cancer was 1.6% in people over 60 with invisible blood in their urine.
A large cohort study of 10,149 patients found no apparent causal link between obstructive sleep apnea and cancer development. However, researchers discovered that low oxygen levels were linked to an increased risk of smoking-related cancers.
Researchers at NYU Langone Medical Center identified a possible new drug target, LUNAR1, for treating childhood blood cancer. Blocking LUNAR1's action stalled leukemia progression and may offer an alternative to standard chemotherapy.
A study analyzing 10 years of data on children with severe combined immune deficiency (SCID) found that early detection through newborn screening and transplantation significantly improves survival rates. Children transplanted before 3.5 months old had excellent survival, regardless of donor source or infection status.
Researchers have devised a simple blood test that can diagnose cancer with high accuracy, saving time and preventing costly procedures. The Lymphocyte Genome Sensitivity (LGS) test measures DNA damage caused by ultraviolet light, distinguishing between cancerous and healthy cells.
Scientists at Barts Cancer Institute have identified a molecule called focal adhesion kinase (FAK) that signals the body to repair itself after chemotherapy or radiotherapy. Removing FAK from blood vessels in melanoma and lung cancer models made treatments more effective, suggesting that targeting this molecule could boost cancer therapy.
A large population-based study of European adults with blood cancers found that regional differences in treatment and care quality contribute to varying survival rates. The study analyzed data from 30 cancer registries covering all patients diagnosed in 20 European countries between 1997 and 2008.
A team of researchers at UT Arlington has developed a low-cost, non-invasive device to detect bladder cancer cells in urine. The device uses nanotechnology and can identify as few as two cancer cells in a full liter of urine, making it a promising tool for early detection.
Researchers at St. Joseph's Hospital and Medical Center discovered a new treatment for ovarian cancer that improves response rates and prolongs time until cancer recurrence. Trebananib, a peptide-Fc fusion protein, targets angiogenesis by inhibiting angiopoietin 1 and 2 binding to the Tie2 receptor.
A study found that childhood cancer survivors were hospitalized more often and for longer durations than the general population, with conditions like blood disorders and infections leading to hospitalizations. The study highlights the need for regular cancer-focused healthcare to identify health problems throughout their lives.
Researchers have developed a lab-on-a-chip platform capable of detecting protein cancer markers in blood at extremely low concentrations, enabling early diagnoses and treatment monitoring. The device's high sensitivity and portability make it an attractive tool for future cancer treatments.
Researchers at Dartmouth's Norris Cotton Cancer Center have discovered a new epigenetic mechanism that distinguishes normal blood stem cells from blood cancers. This finding holds promise for developing targeted treatments that preserve healthy stem cells while killing leukemia cells.
A recent study published in Nature Genetics found a correlation between the loss of the Y chromosome in blood cells and both a shorter life span and higher mortality from cancer in other organs. Men who had lost the Y chromosome in a large proportion of their blood cells had a lower survival rate, irrespective of cause of death.
Researchers at Stanford Medicine have developed a highly sensitive and specific blood test that can accurately identify stage-1 lung cancer patients and detect rare cancer mutations. The CAPP-Seq technique analyzes tumor DNA in the blood to provide non-invasive monitoring of cancer progression and treatment responses.
A new study identified genetic variants associated with increased risk of bladder cancer recurrence. Inheriting certain DNA sequences may affect a patient's prognosis, allowing physicians to tailor surveillance and treatment plans.
Researchers discover MGA controls expression of Bone Morphogenetic Proteins, a crucial step in bone development, and may contribute to tumor formation in adults. The study suggests that MGA's dysfunction could lead to chronic lymphocytic leukemia.
Scientists have discovered two novel genes linked to angiosarcoma, a rare and aggressive cancer of blood vessels. The study found that these genes are mutated in nearly 40% of cases, suggesting potential new targets for treatment.
Researchers at Dana-Farber Cancer Institute found that the normal enzyme SYK pairs with mutated FLT3 to promote AML progression and resistance to treatment. Combination therapy involving SYK and FLT3 inhibitors showed significant promise in treating AML.
Researchers at University of British Columbia have discovered a potential new treatment for Paroxysmal nocturnal hemoglobinemia (PNH), a rare blood cancer that causes red blood cells to become vulnerable to the body's complement immune system. The treatment, aurin tricarboxylic acid (ATA), restores blood cell resistance and may also of...
Scientists at MD Anderson Cancer Center discovered that exosomes, tiny particles shed by cancer cells, contain the entire genetic blueprint of cancer cells. This finding could lead to a blood test that detects cancer gene defects and helps physicians treat patients earlier.
Researchers at Cornell University have discovered a new way to destroy metastasizing cancer cells by hitching killer proteins to white blood cells. The treatment, which uses E-selectin and TRAIL proteins, was found to be nearly 100% effective in killing cancer cells in laboratory tests.
Pediatric leukemia patients can now safely receive intravenous infusions of a reformulated chemotherapy agent, allowing for less frequent treatment and reduced pain. The study found similar efficacy and toxicity profiles between the IV PEG-asparaginase and IM native formulations.
Researchers have made significant strides in expanding transplant eligibility and improving long-term success rates, particularly for older patients. Studies have shown that haploidentical transplants and cord blood cells can be viable alternatives to fully matched donors.
A gene therapy trial has shown promising early results for the 'bubble boy' disease, with 8 out of 9 children treated well. The study used haploidentical transplants and high-dose post-transplantation cyclophosphamide to improve outcomes for patients who were previously ineligible due to a lack of matching donors.
A large study found a significant association between a history of airborne allergies, particularly to plants, grass, and trees, and an increased risk of hematologic malignancies in women. The study suggests that chronic immune stimulation may play a role in the development of blood cancers in women.
A large study of over 30 years found that eating a daily handful of nuts significantly reduces the risk of death from any cause. The study also found that regular nut-eaters were more slender than those who didn't eat nuts, contradicting a common worry about weight gain.
Researchers at Dana-Farber Cancer Institute have identified a protein that increases with endurance exercise and boosts brain health by promoting the growth of new nerves involved in learning and memory. The discovery provides a molecular pathway for exercise's effects on cognitive function, particularly in older adults.
Researchers at NYU Langone are leading a $6.25 million, five-year research initiative to find targeted treatments for children with acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. The project aims to improve the cure rate and reduce mortality rates among ALL patients.
A new survey of nearly 5,000 tumor samples has identified 140 regions with scrambled genetic code believed to contain many undiscovered cancer genes. The mapping gives researchers a starting point to search for oncogenes and tumor-suppressor genes.
A new drug, CMX001, has been shown to prevent a common and sometimes severe viral disease in patients receiving stem-cell transplants. The study found that patients taking the drug were 90% less likely to develop cytomegalovirus (CMV) infection than those taking a placebo.
A study by Karoline Kollmann and colleagues reveals CDK6's role in regulating tumour growth while also promoting blood vessel formation. The researchers found that a mutant form of CDK6 retains its ability to regulate expression despite losing kinase function.
Researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice. These non-replicating particles, derived from rhabdovirus, work by direct cytolysis and induction of antitumor immunity, showing promise as a new therapy for leukemia.
Researchers discovered a new molecular pathway causing heart failure and showed that JQ1 blocks this pathway to protect the heart. The compound works within the cell's nucleus, preventing damaging stress responses.
Researchers have identified glycolysis as a key mechanism for endothelial cell energy production and blood vessel formation. Blocking glycolysis could prevent excessive angiogenesis in diseases like cancer, offering new therapeutic options.
A new study found that regions near petroleum refineries and manufacturing plants releasing benzene have significantly higher non-Hodgkin lymphoma incidence rates. The risk of the disease decreases with increasing distance to these facilities.
Researchers have discovered that cancer cells can fuse with blood cells, enabling them to travel through the body and seed new tumors. This breakthrough has major implications for treating metastatic cancers.
A new study found that DNA abnormalities, specifically clonal mosaic events, are more common in people with type 2 diabetes than the general population. This increase in CMEs may partly explain why individuals with type 2 diabetes have a higher risk of blood cancers like lymphoma and leukaemia.
A new analysis found that African Americans with chronic lymphocytic leukemia present with advanced disease and have shorter survival times than Caucasians. The study suggests that biological factors may account for racial disparities in cancer survival.
Researchers will study pediatric sarcomas, a rare and aggressive form of cancer affecting 11% of all childhood cancers, with the goal of developing new therapies. The project aims to improve outcomes for children with advanced or metastatic disease, who have limited success with current treatments.
Researchers have found antibodies against the human papillomavirus (HPV) that may help predict individuals at risk of HPV-related oropharyngeal cancer. The study found that these antibodies were detectable in nearly 35% of patients with cancer, compared to less than 1% of those without cancer.
A study by Dana-Farber Cancer Institute researchers found that active surveillance and watchful waiting are safe alternatives to initial treatment for men with low-risk prostate cancers. These strategies can lead to better quality of life and reduced healthcare costs, with some patients experiencing up to 13 months additional quality-a...
The Leukemia & Lymphoma Society (LLS) and Dana-Farber Cancer Institute are partnering to establish a network of sites for clinical trial testing in community oncology settings. This partnership aims to increase trial enrollment and advance innovative blood cancer therapies, ultimately saving lives.
A recent study revealed a new mutation in atypical chronic neutrophilic leukemia (CNL) patients, allowing doctors to prescribe targeted treatment ruxolitinib. The treatment brought significant improvements to the patient's health, including reduced white blood cell counts and normalized other blood counts.
Researchers used advanced amplification technology to detect abnormal DNA in blood samples from patients with gastrointestinal stromal tumors (GIST). The new blood test found secondary resistance mutations in the KIT gene, which were missed by traditional tissue analysis.
Researchers at UCLA refine their 'NanoVelcro' device to capture and analyze single cancer cells from patient blood, enabling 'liquid biopsies' for metastatic melanoma. The improved device allows doctors to tailor personalized treatment to specific patients.
Researchers found that women with ovarian cancer had higher blood calcium levels than those without the disease. The study suggests that high calcium levels may be a biomarker for early detection of ovarian cancer.
A recent study published in Mayo Clinic Proceedings found that microscopic hematuria is an unreliable indicator of urinary tract malignant tumors. The study developed a Hematuria Risk Index to predict cancer risk, identifying low-risk patients who may not need further evaluation and reducing unnecessary evaluations.
Dr. James Watson suggests that antioxidants in late-stage cancer cells can promote cancer progression, and that reducing antioxidant levels may be key to developing new anti-metastatic drugs. He calls for a faster timetable for researching this proposition.